The MIMIC® System can capture human diversity. Each well in the MIMIC® System’s 96-well plastic microtiter plate represents a human immune system. MIMIC® highly sensitive functional assays simulate a clinical trial for a diverse population, without ever putting human subjects at risk.
- Vaccine Assessment
- Biologic Drug
MIMIC® technology is based on autologous primary human immune cells. One surrogate human provides all controls (no drug, drug, drug dosing, drug + pathogen) and can be repeated multiple times.
The MIMIC® process can include a diverse donor pool comprising hundreds of individuals.
The MIMIC® System models innate and/or adaptive and functional immune responses; analysis is available for cytokines, APCs, T cells, and B cells for a better selection of drug candidates for clinical evaluation.
Because the MIMIC® System is predictive, it can lead to faster cycle times for discovery and reduce the time and costs to bring drugs to the market.
MIMIC® processing is high-throughput and automated with thousands of assays per month. Learn more about MIMIC® System modules.
Sensitive and Accurate
MIMIC® technology is more sensitive than standard PBMC assays. See our case studies, Peripheral Tissue Equivalent Module Compared to PBMC Assay and Lymphoid Tissue Equivalent Module Versus PBMC Assay, for more details.
|Research||Pre-Clinical Development||Clinical Development||Production|
Vaccines that are effective for more people against more pathogen strains
Evaluate vaccine candidates for safety and effectiveness in humans before clinical development begins to stop failures early
Compare safety and potency of vaccines made with different processes and identify and characterize unexpected results during a clinical trial
MIMIC® technology offers a robust potency assay for release of vaccine
- More accurate than other in vitro assays and animal models
- Find potential immunotoxicity problems earlier in the research and development process
- Enables mechanism of action studies to understand adverse immune responses and find solutions
Standard immunotoxicity tests use in vitro PBMC assays and animal models (usually rodents) to determine whether a drug, vaccine, or other product induces a potentially adverse immune response. Unfortunately, these tests can sometimes produce misleading results. VaxDesign has shown that the MIMIC® System is more sensitive and accurate than standard PBMC assays.
We have also shown that the MIMIC® System reproduces human responses to immunosuppressants and immunopotentiators, in some cases where rodent and non-human primate studies did not.
|Discovery and Early Development||Process Development||Manufacture|